News

Here you can find the latest TOPADUR news & events.

4.4.2023
Press Release

TOPADUR appoints Pascal Brenneisen as Chief Executive Officer

TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.

Read more
9.11.2022
News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

Read more
8.9.2022
News

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.

Read more
27.6.2022
News

Scientific Publication in the International Journal of Molecular Sciences

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.

Read more
20.6.2022
News

Scientific Publication in Advanced Therapeutics

Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.

Read more
19.5.2022
Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

Read more

Do you need more information or references? Media contact

Investors

InvestorsNews & Events

About us

VisionHistoryLeadershipBoard of DirectorsResearch Partners

Pipeline

Wound HealingSkin FibrosisOphthalmologyMedical cosmetics
OncologyLung Fibrosis
‍

Contact

info@topadur.com+41 44 755 44 66
Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
ImpressumLegal Disclaimer